» Articles » PMID: 15341735

The CAP-Gly Domain of CYLD Associates with the Proline-rich Sequence in NEMO/IKKgamma

Abstract

CYLD was originally identified as the human familial cylindromatosis tumor suppressor. Recently, it was reported that CYLD directly interacts with NEMO/IKKgamma and TRAF2 in the NF-kappaB signaling pathway. The two proteins bind to a region of CYLD that contains a Cys-box motif and the third cytoskeleton-associated protein-glycine conserved (CAP-Gly) domain. Here we report that the third CAP-Gly domain of CYLD specifically interacts with one of the two proline-rich sequences of NEMO/IKKgamma. The tertiary structure of the CAP-Gly domain shares the five-stranded beta sheet topology with the SH3 domain, which is well known as a proline-rich sequence-recognition domain. However, chemical shift mapping revealed that the peptide binding site of the CAP-Gly domain is formed without the long peptide binding loop characteristic of the SH3 domain. Therefore, CAP-Gly is likely to be a novel proline-rich sequence binding domain with a mechanism different from that of the SH3 domain.

Citing Articles

A computational approach for structural and functional analyses of disease-associated mutations in the human CYLD gene.

Roy A, Feroz T, Islam M, Munim M, Supti D, Antora N Genomics Inform. 2024; 22(1):4.

PMID: 38907316 PMC: 11184958. DOI: 10.1186/s44342-024-00007-2.


In the moonlight: non-catalytic functions of ubiquitin and ubiquitin-like proteases.

Campos Alonso M, Knobeloch K Front Mol Biosci. 2024; 11:1349509.

PMID: 38455765 PMC: 10919355. DOI: 10.3389/fmolb.2024.1349509.


CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.

Li Y, Yang C, Xie L, Shi F, Tang M, Luo X Cell Death Dis. 2024; 15(1):95.

PMID: 38287022 PMC: 10824711. DOI: 10.1038/s41419-024-06419-w.


CYLD in health and disease.

Marin-Rubio J, Raote I, Inns J, Dobson-Stone C, Rajan N Dis Model Mech. 2023; 16(6).

PMID: 37387450 PMC: 10320722. DOI: 10.1242/dmm.050093.


The Potential of Cylindromatosis (CYLD) as a Therapeutic Target in Oxidative Stress-Associated Pathologies: A Comprehensive Evaluation.

Huang Z, Tan Y Int J Mol Sci. 2023; 24(9).

PMID: 37176077 PMC: 10179184. DOI: 10.3390/ijms24098368.